Showing 4841-4850 of 6036 results for "".
- Allergan to Present New Data from its Eye Care Portfolio at the 2021 ASCRShttps://modernod.com/news/allergan-to-present-new-data-from-its-eye-care-portfolio-at-the-2021-ascrs/2479386/Allergan announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) annual meeting being held July 23-27 in Las Vegas. Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an i
- Euclid Systems Appoints Vance Thompson, MD, as Chief Medical Officerhttps://modernod.com/news/euclid-systems-appoints-vance-thompson-md-as-chief-medical-officer/2479383/Euclid Systems announced that it has appointed Vance Thompson, MD, an internationally recognized authority in laser vision correction and advanced cataract surgery, to the position of Chief Medical Officer. As an international researcher, Dr. Thompson has played a key role in the development of a
- Allegro Ophthalmics to Present the Results of ALG-1007 Ex-U.S. Phase 2 Clinical Trial for Dry Eye Disease at ASCRShttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-alg-1007-ex-u-s-phase-2-clinical-trial-for-dry-eye-disease-at-ascrs/2479379/Allegro Ophthalmics announced that the results of the company’s second ALG-1007 ex-U.S. clinical trial for the treatment of dry eye disease (DED) will be presented during the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) an
- iSTAR Medical Receives FDA Approval to Begin Trial for MINIject for Patients With Glaucomahttps://modernod.com/news/istar-medical-receives-fda-approval-to-begin-trial-for-miniject-for-patients-with-glaucoma/2479375/iSTAR Medical announced that the FDA granted it investigational device exemption (IDE) to start a trial with MINIject. The STAR-V study will investigate MINIject in over 350 patients with primary open-angle glaucoma. Glaucoma surgeons in the United States, Canada, and Europe will join the trial.<
- First Eye Care-Focused SPAC, LifeLong Vision, Launchedhttps://modernod.com/news/first-eye-care-focused-spac-lifelong-vision-to-host-launch-event/2479368/A new multi-billion dollar initiative that aims to provide daily access to eye care through any mobile device officially launched on Wednesday. LifeLong Vision, which is backed by investment banking platform MedHealth Capital, is set to emerge via a Special Purpose Acquisition Company (SPA
- CATS Tonometer Receives FDA Clearance for Disposable Tonometer Prismhttps://modernod.com/news/cats-tonometer-receives-fda-clearance-for-disposable-tonometer-prism/2479364/The CATS-D Disposable Prism, designed to deliver improved IOP measurement accuracy using a sterile, disposable tip replacement for the Goldmann Tonometer, received FDA clearance and will be available for sale in the fall of 2021. “The CATS Tonometer Prism is designed to provide more accura
- Notal Vision Announces Publication First Prospective Longitudinal Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-first-prospective-longitudinal-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479365/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated Home OCT for wet age-related macular degeneration (AMD) patients have been published in
- Notal Vision Announces Publication of First Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-of-first-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479356/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated home OCT for wet age-related macular degeneration
- Bausch + Lomb Completes Enrollment of Second Phase 3 Study for NOV03https://modernod.com/news/bausch-lomb-completes-enrollment-of-second-phase-3-study-for-nov03/2479349/Bausch + Lomb and Novaliq announced the second of two phase 3 (MOJAVE) studies evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dy
- NovaSight Announces Establishment of Three Unique CPT Codes for the CureSight Digital Treatment for Lazy Eyehttps://modernod.com/news/novasight-announces-establishment-of-three-unique-cpt-codes-for-the-curesight-digital-treatment-for-lazy-eye/2479343/NovaSight announced that it has reached several key milestones that signal progress toward the launch of its CureSight digital treatment device for amblyopia (lazy eye) and the establishment of a reimbursement structure for the physicians and patients who use it. NovaSight took an importan